Items Tagged with 'Pfizer'
Purchase ceiling raised for two stock picks.
In light of significant recent developments, The Turnaround Letter is raising its maximum buy price for these large cap purchase recommendations.Read More
PFE Complete $11.85 billion Sale
On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.
PFE Announces Revenues of $14.0 billion
On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.
PFE Reports Second Quarter 2012 Revenues of $15.1 Billion
On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.
PFE Obtains FDA Approval for Lyrica
On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
PFE Reports 7% Revenue Decrease
On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.
PFE to Divest Nutrition Business
On April 23, 2012, Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement to divest its Nutrition business to Nestle for $11.85 billion in cash.
Pfizer Buys Vitamin C Icon
On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....
On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.
On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
George Putnam's Favorite Stocks for 2016
Distressed Investing Blog
Selecting a turnaround stock with solid profit potential can almost be considered an art form in itself. As noted in our other distressed investing blog entries there are many factors to evaluate to determine the real possibilities in any turnaround situation, and here is one more: Look for solid core businesses.
Your Financial Security is Serious Business...
so why should you trust The Turnaround Letter?
The Turnaround Letter's 15-year returns were 11.3%--vs. S&P's 4.4%
30 Years of Turnaround Investing Experience & Reliable Stock Market Advice
2016's Closed Out Purchase Recommendations Averaged 49% Stock Profit
Diverse Monthly Stock Picks Personally Selected by George Putnam
Banking on a Financial Sector Turnaround
MoneyShow.com recently tapped George's favorable opinion for a banking industry rebound. In "Turnaround Expert's Banking Bets," Steve Halpern highlights a trio of Putnam's top stock picks from the battered financial sector.
George reminds value investors: "Fortunately, many of the factors...just aren't present in the market, and the other reason that investors seem to be down on the banks is they sort of expected the Fed to raise interest rates a little faster than they have. And the banks do better when interest rates are rising because they have wider margins on their loans, but I think the Fed will gradually raise rates to we will see profits improve, and so I think this downturn is really temporary."
Get more stock market advice.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.